Company Profile

Protein Sciences Corporation (AKA: PSC)
Profile last edited on: 6/17/2021      CAGE: 1EAP2      UEI: NW32L3GCTBM8

Business Identifier: Vaccines and therapeutic proteins for infectious diseases
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1000 Research Parkway
Meriden, CT 06450
   (203) 686-0800
Location: Single
Congr. District: 05
County: New Haven

Public Profile

In August 2017, Sanofi's acquisition of Proteien Sciences was finalized with the transaction in major part, it would seem, due to the smaller firm's strong position the flu vaccine space, More than once in earlier years, the firm had been indicated as being acquired only to have the deal(s) fall through. Protein Sciences Corporation (PSC) had been a biopharmaceutical service company focused on proprietary vaccine development and manufacturing, as well as the development of antigens for scientific research. PSC used the Baculovirus Expression Vector System (BEVS) on a commercial scale. Applications of the BEVS include prophylactic vaccines, therapeutic vaccines, gene therapy, and biologics. The company had partnered with pharmaceutical, biotechnology and genomics companies aiming to proceed from a gene target to a commercial vaccine, therapeutic, or screening molecule. The company's products include the Flublok influenza vaccine, the Diamyd therapeutic vaccine for type I diabetes, and the Glybera gene therapy for lipoprotein lipase deficiency. The cmpany is also developing candidate vaccine for possible pandemic-causing viruses such as the H1N1 swine and H5N1 and H7N9 avian influenza viruses and for Severe Acute Respiratory Syndrome (SARS).

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2016 2 NIH $1,354,000
Project Title: Production and Evaluation of a Vault-CCL21 Nanocapsule as a Lung Cancer Treatment
2015 1 Army $99,999
Project Title: Next-Generation Adenovirus Vaccine
2006 2 CBD $848,764
Project Title: Improved Protein Manufacturing in Insect Expression Systems
2005 1 NIH $99,866
Project Title: Award made but no title provided

Key People / Management

  Daniel D Adams -- Executive Chairman and Global Head of Business Development

  Manon M J Cox -- President and Chief Executive Officer

  George W Buchman

  Lisa M Dunkle -- Chief Medical Officer

  Timothy J Fields -- Senior Vice President Quality

  Mireli W Fino -- Senior Vice President, Manufacturing Operations

  Wayne Hachey -- Head of Government and Clinical Affairs

  Christine Izzo -- Controller

  Mark Michalik -- Vice President of Operations

  Ljiljana Minwalla -- General Counsel / Secretary

  Penny L Post -- Vice President of Quality and Regulatory Affairs

  Joseph Rininger

  Indresh K Srivastava -- Vice President, Product Realization

  Zhendong Wang

  Nadine Francis West -- Senior Vice President, Chief Administrative Officer and Corporate Secretary